Research

*November 2021* Although next-generation TKIs, such as osimertinib (Tagrisso), have helped to overcome resistance in EGFR-mutated non–small cell lung cancer (NSCLC), a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs, as well, according to Roy S. Herbst, MD,…

*October 2021* Highlights Acquired resistance mechanisms to osimertinib can be EGFR dependent or independent. First- and fourth-generation EGFR-TKIs are able to overcome EGFR-dependent resistance. MET and MEK inhibitors may overcome EGFR-independent resistance. Anti-HER/MET novel monoclonal antibody seems effective across multiple resistance mechanisms. Carboplatin/paclitaxel ± bevacizumab/atezolizumab represents a feasible option in…

*November 2021* Note: The article below, In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer, is taken from CancerConnect and lists and explains the different generations of TKIs, their modes of action and  resistance mechanisms that develop as well as their treatments. EGFR-targeted drugs that have been shown to benefit…

*October 2021* Purpose: This study aimed to explore the clinical value of SBRT for primary lung lesions of EGFR-mutant NSCLC patients with non-oligometastatic disease during first-line EGFR-TKI treatment. Methods: We identified patients with stage IV EGFR-mutant non-oligometastatic NSCLC who were suitable to receive SBRT for the primary tumors after EGFR-TKI treatment. All…

*October 2021* The understanding of EGFR signaling in non–small cell lung cancer (NSCLC) continues to evolve, helping to spark the development of novel therapies for new patient populations with uncommon alterations. In May, the FDA granted an accelerated approval to amivantamab-vmjw (Rybrevant) for patients with locally advanced or metastatic NSCLC…